Answers are grounded in this paper and cite their sources.
Young women with autoinflammatory diseases on long term IL-1 blockade are increasingly asking about the feasibility, safety and outcomes of pregnancy but few data are available. The FDA classes anakinra as pregnancy risk grade B and rilonacept and canakinumab as grade C. The manufacturers advise that there are no data on the outcome of pregnancy or on excretion into breast milk and that anakinra and canakinumab should only be taken if the benefits outweigh risk; for rilonacept the advice is to avoid in pregnancy. The literature contains only 3 reported cases of use of anakinra in pregnancy – all in adult onset Stills disease (AOSD) and with successful outcomes.
No takes yet. Share an insight, caveat, or question.
Lachmann et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: